Comment on “Efficacy and safety of atezolizumab and bevacizumab with or without TACE as first-line therapy for unresectable HCC: a multicenter cohort study”

Hepatology International 2026

View at publisher

Authors: Huikang Wang, Xinjun Xu, Xicheng Song, Y. Zhang

DOI: 10.1007/s12072-025-10970-9

Cited by: 0

References: 5

Fields of Study & Subjects

HER2/EGFR in Cancer Research Colorectal Cancer Treatments and Studies Cancer Immunotherapy and Biomarkers

References 5